North China Pharmaceutical announced that the company and its subsidiary Xiantai participated in the tenth batch of national centralized procurement of Pharmaceuticals, and all four varieties are proposed for selection, including injectable penicillin sodium, injectable piperacillin sodium, injectable ampicillin sodium, and injectable ampicillin sodium-sulbactam sodium. The prices of the proposed selected Pharmaceuticals have decreased compared to the original selling prices. In 2023, the sales revenue of injectable penicillin sodium was 0.129 billion yuan, accounting for 1.28% of the annual revenue. If confirmed as selected and a purchase and sale contract is signed, the company will fully ensure supply according to the selected area's demand and promote the increase of related products in the selected area and the development of the off-market.